Loading
Every dated change on the records linked to Biochemical recurrence of prostate cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Event-free survival hazard ratio 0.
Five-year event-free survival 92 percent with adjuvant against 90 percent with salvage radiotherapy (hazard ratio 0.
Progression at 6 months 19 percent after stereotactic ablative radiotherapy against 61 percent under observation (p=0.
Five-year biochemical progression-free survival 85 percent with adjuvant against 88 percent with early salvage radiotherapy (hazard ratio 1.
Five-year freedom from biochemical progression 87 percent with early salvage against 86 percent with adjuvant radiotherapy (hazard ratio 1.
A milestone in how this cancer is treated.